VIR-5500
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone-refractory Prostate Cancer
Conditions
Hormone-refractory Prostate Cancer
Trial Timeline
Aug 10, 2023 → Sep 29, 2027
NCT ID
NCT05997615About VIR-5500
VIR-5500 is a phase 1 stage product being developed by Vir Biotechnology for Hormone-refractory Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05997615. Target conditions include Hormone-refractory Prostate Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05997615 | Phase 1 | Recruiting |
Competing Products
8 competing products in Hormone-refractory Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| YM598 | Astellas Pharma | Phase 2 | 52 |
| Zoledronic acid + Estramustine + Docetaxel | Novartis | Phase 2 | 52 |
| amg 162 | Amgen | Phase 3 | 76 |
| Denosumab | Amgen | Phase 3 | 76 |
| IV Bisphosphonate q 4 weeks | Amgen | Phase 2 | 51 |
| Dasatinib | Bristol Myers Squibb | Phase 2 | 51 |
| ILX651 | Sanofi | Phase 2 | 51 |